TRIN-GYI-PHO-NYA: TIBET’S ENVIRONMENT AND DEVELOPMENT DIGEST
Vol. 2, No. 6
Tibetan medicine has become a lucrative business yielding million-dollar profits to large pharmaceutical companies in China. Various new policies have been instituted to standardize the production and distribution of Tibetan medicinal products, mainly for commercial and bureaucratic reasons. These new policies are proving to be a debilitating legal framework for the persevering practitioners of the unique Buddhist healing tradition.
According to a study, there are 75 pharmaceutical companies dealing with Tibetan medicine in various corners of the Tibetan Plateau, out of which 30 are run by Tibetans. While the spiritual guidelines of making medicine according to the Buddhist medical texts – Gyushi – are increasingly compromised with the onslaught of industrial production of Tibetan medicine, an interesting issue that comes to point is regarding the efficacy of the healing powers of these medicine. “Amchi (Tibetan doctor) makes medicine to heal the patient but the pharmaceutical companies make medicine to reap profits,” explained a concerned Tibetan doctor from Amdo (now incorporated in Qinghai Province).
New government regulations require all Tibetan doctors to go through a cumbersome registration process. When approved, they are allowed to sell medicine, but only to their private patients. Rinchen-Tsotru-Dashel, a pill that normally costs 20 yuan, is now being sold for 50 yuan by pharmaceutical companies.
“Soon, we will be barred from producing these medicines as Chinese companies are gaining patents over different Tibetan medicines,” said the doctor. To the Tibetan people, the long-term issues involve the survival of this centuries-old healing tradition, as well as the access members of the community have to the tradition. Surely the ultimate subversion of the Tibetan medical tradition would be if the Tibetan people themselves were forced to purchase medicine invented by their own culture and made from their own land, at a higher cost, and from a Chinese company because of a contrived patent system set-up to benefit large industries to the exclusion of local practitioners.
Commercialization of Tibetan medicine also has environmental consequences. Most of Tibetan medicine’s plant ingredients are rare herbs that are endemic to Tibet’s high mountains. Currently, there are no mechanisms in place to check indiscriminate harvesting of these species. The commercialization of Tibetan medicine has dramatically increased demands for these ingredients, resulting in the widespread, unsustainable removal of certain plant species. Utpal Ngonpo (Blue poppy, meconopsis sp.), marketed as a cure for Hepatitis B by Chinese companies, is one such rare plant species that the Tibetan doctor fears might not survive if the current rate of harvesting continues.
The challenge for policy makers in China is not just the integration Tibetan medicine into the mainstream economy and modes of production, but also the preservation and promotion of a unique tradition of medical knowledge and expertise. While greater access to, and availability of, Tibetan medicine is a worthwhile goal, it will mean very little if the tradition which produced it is swallowed up and destroyed in the process.
